Experimental triple therapy shows promise for stubborn tumors
NCT ID NCT03388632
First seen Jan 04, 2026 · Last updated May 11, 2026 · Updated 21 times
Summary
This early-phase study tested a combination of three drugs—interleukin-15 (IL-15), nivolumab, and ipilimumab—in 31 adults with cancers that no longer respond to standard treatments. The goal was to find the safest dose and see if the drugs could help the immune system attack tumors. Participants received the drugs in cycles, with close monitoring for side effects. The study focused on safety and dosing, not on curing the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.